OS Therapies (OSTX) Proxy filing summary

Executive summary

• The 2026 Annual Meeting will be held virtually on September 9, 2026, with shareholders voting on director elections, an amended incentive plan, auditor ratification, and other business.

• Shareholders of record as of July 21, 2026, are eligible to vote, with 45,538,101 shares of common stock and 392,500 shares of Series A preferred stock outstanding.

• Proxy materials, including the Proxy Statement and 2025 Annual Report, are available online, and voting can be done via Internet or mail.

Voting matters and shareholder proposals

• Proposals include electing six directors, approving the amended 2023 Incentive Compensation Plan, ratifying MaloneBailey, LLP as auditor, and other business.

• Board recommends voting FOR all director nominees, the amended plan, and auditor ratification.

• Shareholder proposals for the 2027 meeting must be received by March 26, 2027, for inclusion in the proxy statement.

Board of directors and corporate governance

• Board consists of six members, with five deemed independent; Paul A. Romness serves as Chairman and CEO.

• Committees include Audit, Compensation, and Nominating and Corporate Governance, each with defined responsibilities and independent members.

• Board meetings include executive sessions without employee directors; all directors attended at least 75% of meetings in 2025.

• Written code of business conduct and ethics applies to all directors, officers, and employees.